Recent Updates
Recently added Catalysts

INS117548

Phase 1

Glaucoma | Small molecule | Ophthalmology |Merck & Company, Inc.|Last Updated: Oct 2, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment84
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00767793A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)PHASE1 COMPLETED 84Sep 1, 2008May 1, 2009Oct 2, 2015 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Incidence of adverse events
15
Rate of discontinuation
15
Changes in: >Ophthalmic exam parameters >Corneal thickness >Intraocular pressure >Visual Acuity >Physical exam, vital signs and laboratory parameters
15
Compliance
15
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Arm 1PLACEBO_COMPARATOROne drop in each eye every 12 hours for seven days
Arm 2EXPERIMENTALOne drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
Arm 3EXPERIMENTALOne drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
Arm 4EXPERIMENTALOne drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
Interventions
NameTypeDescription
PlaceboDRUGOne drop in each eye every 12 hours for seven days
INS117548DRUGOne drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 80 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Have a diagnosis of bilateral ocular hypertension or early primary open angle glaucoma * Have best corrected visual acuity in both eyes of at least +0.5 or better Exclusion Criteria: * Are diagnosed with closed angle glaucoma, exfoliation syndrome or exfoliation glaucoma, an...

Unlock Eligibility Criteria